These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1706794)

  • 1. Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity.
    Barrett JA; Woltmann RF; Swillo RS; Kasiewski C; Faith WC; Campbell HF; Perrone MH
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):537-45. PubMed ID: 1706794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties.
    Mochizuki N; Uchida S; Miyata H
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):983-95. PubMed ID: 7687727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties.
    Eigenmann R; Gerold M; Holck M
    J Cardiovasc Pharmacol; 1984; 6(3):511-9. PubMed ID: 6202980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties.
    Narimatsu A; Kitada Y; Satoh N; Suzuki R; Okushima H
    Arzneimittelforschung; 1987 Apr; 37(4):398-406. PubMed ID: 3606694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular pharmacology of RS-1893, an orally active cardiotonic agent with arterial and venous vasodilator actions.
    Miyake S; Shiga H; Koike H; Mizuno H; Yorikane R; Oda T; Iijima Y; Kumakura S; Morisawa Y
    Jpn J Pharmacol; 1988 Jul; 47(3):273-83. PubMed ID: 2851676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular pharmacology of the vasodilator-cardiotonic agent, 349U85.
    Steffen RP; Wastila WB
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):579-89. PubMed ID: 1280714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
    Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T
    Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of action.
    Hayes JS; Pollock GD; Wilson H; Bowling N; Robertson DW
    J Cardiovasc Pharmacol; 1987 Apr; 9(4):425-34. PubMed ID: 2438505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activities.
    Hayes JS; Pollock GD; Wilson H; Bowling N; Robertson DW
    J Pharmacol Exp Ther; 1985 May; 233(2):318-26. PubMed ID: 3999023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS; Harkin CP; Hettrick DA; Warltier DC
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes].
    Ohhara H; Sawada K; Ogawa T; Takeda M; Igarashi T
    Nihon Yakurigaku Zasshi; 1992 Jun; 99(6):421-33. PubMed ID: 1398339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
    Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
    J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).
    Dage RC; Roebel LE; Hsieh CP; Weiner DL; Woodward JK
    J Cardiovasc Pharmacol; 1982; 4(3):500-8. PubMed ID: 6177949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic profile of the cardiotonic agent pimobendan.
    van Meel JC; Diederen W
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action.
    Gristwood RW; Comer MB; Eden RJ; Taylor EM; Turner JA; Wallduck M; Owen DA
    Br J Pharmacol; 1988 Apr; 93(4):893-901. PubMed ID: 3390657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative.
    Gras J; Cardelús I; Beleta J; Gristwood RW; Palacios JM; Llenas J
    Arzneimittelforschung; 2000 Nov; 50(11):980-6. PubMed ID: 11148864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.